(Reuters) -Johnson & Johnson said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external evaluation study.

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S.

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

Johnson & Johnson (JNJ) stock fell after pausing use of its Varipulse Pulsed Field Ablation Platform. Read more here.

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...